Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06006546 · ClinicalTrials.gov registry record · Phase 1
The Study of Immunization in People Living With HIV Undergoing an ATI for Elicitation of VRC01-lineage Antibodies
A Phase 1 study of Chronic HIV Infection, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- Active
- Registry status
- Phase 1
- Development phase
- 35
- Enrollment target
- 8
- Study locations
NCT06006546 is a Phase 1 study of Chronic HIV Infection that is active but no longer recruiting, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 35 participants. The trial reports 8 study locations across 6 states.
The verdict
NCT06006546, a Phase 1 study of Chronic HIV Infection, is active but no longer recruiting, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 35 participants
- Enrollment target
- 8
- Study locations
Study Summary
This is a multicenter controlled interventional trial. This phase 1 trial is the first study to assess 426c.Mod.Core-C4b adjuvanted with 3M-052-AF + aluminum hydroxide suspension (Alum) in people living with HIV (PLWH).
Conditions Studied
Interventions
- BIOLOGICAL 426c.Mod.Core-C4b
- OTHER Adjuvant 3M-052-AF+Alum
Study Locations (8)
Georgia
- Atlanta- Ponce - Atlanta
- The Hope Clinic of the Emory Vaccine Center CRS (Site #31440) - Decatur
Washington
- Seattle Vaccine and Prevention CRS (Site # 30331) - Seattle
- Fred Hutchinson Cancer Research Center - Seattle
Alabama
- Birmingham - Birmingham
Massachusetts
- BIDMC - Boston
New York
- Columbia P&S CRS Site#30329 - New York
Pennsylvania
- University of Pittsburg - Pittsburgh
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 35 participants |
| Start Date | 2024-01-03 |
| Est. Completion | 2026-10-27 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06006546
The ClinicalTrials.gov registry entry for NCT06006546 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 35 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Chronic HIV Infection appearing as the primary indexed condition, and to 2 interventions - of which 426c.Mod.Core-C4b is the first listed.
NCT06006546 reports 8 study locations spanning 6 distinct geographic areas - top geographies include Georgia, Washington, Alabama.
Frequently Asked Questions
What is clinical trial NCT06006546 about?
NCT06006546 is a clinical study titled "The Study of Immunization in People Living With HIV Undergoing an ATI for Elicitation of VRC01-lineage Antibodies". This is a multicenter controlled interventional trial. This phase 1 trial is the first study to assess 426c.Mod.Core-C4b adjuvanted with 3M-052-AF + aluminum hydroxide suspension (Alum) in people living with HIV (PLWH).
What is the current status of trial NCT06006546?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 35 participants. The study started on 2024-01-03. Estimated completion is 2026-10-27.
What conditions does trial NCT06006546 study?
This clinical trial studies the following conditions: Chronic HIV Infection.
What interventions are being tested in trial NCT06006546?
The interventions under investigation include: 426c.Mod.Core-C4b (BIOLOGICAL), Adjuvant 3M-052-AF+Alum (OTHER).
Who is sponsoring clinical trial NCT06006546?
This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06006546 being conducted?
This trial has 8 study locations across Alabama, Georgia, Massachusetts, New York, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.